David Meek­er adds an­oth­er biotech board spot to the post-Gen­zyme re­sume; J&J’s DePuy ac­quires 3D print­ing tech for bone heal­ing

→ Soon-to-be-ex-Gen­zyme head David Meek­er has added an­oth­er biotech board po­si­tion to his re­sume. Just a few days af­ter be­ing named chair­man at Rhythm, South San Fran­cis­co-based MyoKar­dia has named Meek­er to the board. Meek­er will be leav­ing Gen­zyme af­ter a long ca­reer in June.

J&J’s DePuy Syn­thes Prod­ucts has ac­quired 3D print­ing tech­nol­o­gy from Tis­sue Re­gen­er­a­tion Sys­tems. DePuy plans to use the tech­nol­o­gy to “cre­ate pa­tient-spe­cif­ic, biore­sorbable im­plants with a unique min­er­al coat­ing in­tend­ed to sup­port bone heal­ing in pa­tients with or­tho­pe­dic and cran­iomax­illo­fa­cial de­for­mi­ties and in­juries.” Fi­nan­cial terms of the trans­ac­tion have not been dis­closed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.